Topic: patent infringement
The patent pillars that have supported Teva’s defense of blockbuster Copaxone continue to fall with Mylan winning another legal battle In the U.K.
An appeals court today tossed out a ban on Sanofi and Regeneron’s cholesterol drug Praluent and ordered a new trial in the patent fight with Amgen.
Allergan is trying to fight off a cadre of generics makers intent on copying its blockbuster eye medication Restasis.
The U.K. Supreme Court has handed Eli Lilly a huge patent victory for its cancer drug Alimta in a battle with Actavis, protecting some European sales.
A federal jury has found that Teva must pay GlaxoSmithKline $235 million in a carve-out patent case over heart drug Coreg.
It was destined to happen: Amgen has sued Sanofi and Regeneron, claiming their newly approved Dupixent infringes one of its antibody patents.
Pfizer and Bristol-Myers Squibb are erecting a wall of patent infringement lawsuits that they hope will slow the advance of generic versions of their shared blockbuster Eliquis.
Big Pharma figures the Amgen vs. Sanofi patent decision, when it comes, could upturn their pipeline drugs and development choices, so they're weighing in.
It looks like we might be in for another big patent brawl between Sanofi and Regeneron on one side and Amgen on the other.
Regeneron and Sanofi won’t have to pull Praluent off the market, at least not yet. A U.S. appeals court has stayed an injunction against the drug, pending an appeal in a fierce PCSK9 patent fight with Amgen.